Skip to main content
. Author manuscript; available in PMC: 2014 Mar 12.
Published in final edited form as: Oral Oncol. 2013 Aug 3;49(10):991–997. doi: 10.1016/j.oraloncology.2013.07.006

Figure 1.

Figure 1

In vitro proliferation of HNSCC cells FADU (A), OSC-19 (B), Cal27 (C) and SCC-1 (D) was significantly reduced following treatment with EDC22 (0–5.0 μg/mL) for 48 h and 72 h and with anti-CD147 mAb (200 μg/mL) for 48 h. Statistical significance by unpaired t-test, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Columns, mean for triplicate and bars, SD.